October 13, 2017
Article
Primary central nervous system lymphoma (PCNSL) is a rare but aggressive malignancy that accounts for approximately 3% of all primary CNS cancer. New studies have changed the landscape of PCNSL treatment paradigms and expectations for outcome.
NeuroVoices: Michael Sughrue, MD, on the Future of Brain Mapping and Utilizing Advanced Technology
The Mobile Stroke Unit Paradigm Shift for EMS: Thomas Topley
American Stroke Association Publishes Updated Guidance for Intracerebral Hemorrhage
FDA Accepts New Drug Application for Intranasal Zavegepant to Treat Acute Migraine